$\mathbf{K} \div \mathbf{d}$: Pulmonary brosis; Lung disease; Pathogenesis; Clinical manifestations; Diagnosis; Management strategies; High-resolution computed tomography; Pulmonary function tests; Lung transplantation; Precision medicine; Emerging therapies.

I d c

Pulmonary brosis is a chronic and progressive lung disease characterized by the scarring and thickening of lung tissue, leading to impaired lung function and di culty breathing [1,2]. Despite being relatively rare, a ecting approximately 5 million people worldwide, pulmonary brosis poses signi cant challenges to both patients and healthcare providers due to its debilitating nature and limited treatment options. In this review, we delve into the pathogenesis, clinical manifestations, diagnosis, and management strategies of pulmonary brosis to provide a comprehensive understanding of this complex condition.

Pa ÷ ÷

The exact cause of pulmonary brosis remains elusive, but it is believed to result from a combination of genetic predisposition, environmental exposures, and aberrant immune responses. Various factors such as cigarette smoking, occupational hazards (e.g., asbestos, silica), viral infections, and certain medications have been implicated in the development of pulmonary brosis [3,4]. The hallmark pathological feature is the excessive accumulation of extracellular matrix proteins, primarily collagen, leading to the formation of scar tissue in the lungs. Dysregulated epithelial cell repair, broblast activation, and inflammatory processes play pivotal roles in perpetuating the brotic cascade.

C ca a 🛵 a

The clinical presentation of pulmonary brosis is heterogeneous, with symptoms ranging from subtle breathlessness on exertion to severe respiratory failure. Common symptoms include progressive dyspnea, persistent cough, fatigue, and unintended weight loss [5-7]. As the disease advances, patients may experience clubbing of the ngers, cyanosis, and signs of right-sided heart failure. The insidious onset and nonspeci c nature of symptoms often result in delayed diagnosis, contributing to poorer outcomes.

Accurate diagnosis of pulmonary brosis requires a systematic approach encompassing clinical evaluation, radiological imaging, pulmonary function tests, and histopathological examination. High-resolution computed tomography (HRCT) of the chest is the cornerstone of radiological assessment, revealing characteristic indings such as reticular opacities, honeycombing, and traction bronchiectasis [8,9]. Pulmonary function tests demonstrate restrictive ventilatory impairment, reduced lung volumes, and impaired gas exchange. In select cases, surgical lung biopsy may be warranted to con rm the

more e ective treatments and personalized management strategies [10]. Additionally, e orts to enhance early detection and establish collaborative research networks are essential for improving patient outcomes and unraveling the complexities of this debilitating disease.

C c

Pulmonary brosis represents a formidable clinical challenge characterized by progressive lung scarring and functional decline. Timely recognition, accurate diagnosis, and comprehensive management are paramount in mitigating disease burden and optimizing patient care. Ongoing research endeavors hold the key to unlocking novel therapeutic interventions and advancing our understanding of pulmonary brosis, ultimately fostering hope for patients a ected by this devastating condition.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of

7 6 1000172